Neoadjuvant HER2+ Articles

Options Shift Paradigm of Locally Advanced HER2+ Breast Cancer
Theresa Shao, MD, discusses the neoadjuvant and adjuvant findings with pertuzumab as well as the adjuvant use of neratinib in patients with locally advanced HER2-positive breast cancer.
HER2+ Breast Cancer Treatment Evolving With New Data, Novel Agents
Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.
Margetuximab Improves PFS in Metastatic HER2+ Breast Cancer
Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.
FDA Approval Sought for Adjuvant T-DM1 in High-Risk HER2+ Breast Cancer
Genentech has completed its FDA submission of a supplemental Biologics License Application for ado-trastuzumab emtansine as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy.
New Findings Expand Options in Early HER2-Positive Breast Cancer
During a recent OncLive Peer Exchange®, panel members discussed the use of HER2-targeted therapies in patients with early-stage HER2-positive breast cancer in the neoadjuvant and adjuvant settings. 
Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.
SABCS 2018 Showcased Practice-Changing Advances in Breast Cancer
Stephen C. Malamud, MD, reflects on the intriguing and practice-changing data presented at the 2018 SABCS.
Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer
Mothaffar F. Rimawi, MD, discusses the current options in HER2-positive breast cancer and sheds light on where future research is headed.
Drugs Make Progress in Breaching the Blood-Brain Barrier
Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.
Patients with HER2-positive early or locally advanced breast cancer who were exposed to reference trastuzumab lots with a marked downward shift in antibody-dependent cell-mediated cytotoxicity (ADCC) had worse outcomes than those not exposed to at least 1 shifted ADCC lot or those treated with its biosimilar.
Publication Bottom Border
Border Publication